These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18827494)

  • 1. Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel.
    Yamamoto H; Sekine I; Yamada K; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
    Oncology; 2008; 75(3-4):169-74. PubMed ID: 18827494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
    Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
    Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
    Scagliotti G; Novello S; von Pawel J; Reck M; Pereira JR; Thomas M; Abrão Miziara JE; Balint B; De Marinis F; Keller A; Arén O; Csollak M; Albert I; Barrios CH; Grossi F; Krzakowski M; Cupit L; Cihon F; Dimatteo S; Hanna N
    J Clin Oncol; 2010 Apr; 28(11):1835-42. PubMed ID: 20212250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
    J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.
    Tell R; Sederholm C; Klintenberg C; Franksson L; Brandén E; Hillerdal G; Lönn U; Lindén CJ; Ewers SB; Lamberg K; Mrazek E; Lödén B; Sjögren A; Linné T; Friesland S; Sirzén F
    Anticancer Res; 2008; 28(5B):2851-7. PubMed ID: 19031924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
    Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer.
    Hensing TA; Schell MJ; Lee JH; Socinski MA
    Lung Cancer; 2005 Feb; 47(2):253-9. PubMed ID: 15639724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
    Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
    J Clin Oncol; 2008 Jan; 26(1):54-9. PubMed ID: 18165640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
    Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy.
    Yoh K; Kubota K; Kakinuma R; Ohmatsu H; Goto K; Niho S; Saijo N; Nishiwaki Y
    Lung Cancer; 2007 Oct; 58(1):73-9. PubMed ID: 17548127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
    Lilenbaum RC; Herndon JE; List MA; Desch C; Watson DM; Miller AA; Graziano SL; Perry MC; Saville W; Chahinian P; Weeks JC; Holland JC; Green MR
    J Clin Oncol; 2005 Jan; 23(1):190-6. PubMed ID: 15625373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy.
    Sekine I; Sumi M; Ito Y; Tanai C; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
    Jpn J Clin Oncol; 2009 Nov; 39(11):707-12. PubMed ID: 19692418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
    Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G
    Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
    Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
    J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non-small-cell lung cancer.
    Iranzo V; Bremnes RM; Almendros P; Gavilá J; Blasco A; Sirera R; Camps C
    Lung Cancer; 2009 Jan; 63(1):63-7. PubMed ID: 18550204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.
    Charoentum C; Thongprasert S; Chewasakulyong B
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1603-7. PubMed ID: 17940374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
    Ramalingam S; Perry MC; La Rocca RV; Rinaldi D; Gable PS; Tester WJ; Belani CP
    Cancer; 2008 Aug; 113(3):542-6. PubMed ID: 18512224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
    Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.